ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1102

Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment

Coen van der Meulen1, Lotte van de Stadt1, Féline Kroon2, Marion Kortekaas1, Annelies Boonen3, Stefan Böhringer4, Monique Reijnierse2, Frits Rosendaal2, Naghmeh Riyazi5, Mirian Starmans6, Franktien Turkstra7, Jende Van Zeben8, CF Allaart2 and Margreet Kloppenburg2, 1LUMC, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Maastricht University Medical Center, Maastricht, Netherlands, 4LUMC, Leiden, 5HAGA ziekenhuis, the hague, Netherlands, 6Zuyderland MC, Heerlen, Netherlands, 7Reade, Amsterdam, Netherlands, 8Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands

Meeting: ACR Convergence 2020

Keywords: hand, Osteoarthritis, pain, quality of life, SF36

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2020

Session Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To investigate whether neuropathic pain is present in patients with inflammatory hand OA, to investigate characteristics of those patients and the impact of neuropathic pain on quality of life (QoL), and whether  neuropathic pain is influenced by anti-inflammatory treatment.

Methods: Data from a randomized, double-blind, placebo-controlled trial in which 92 patients with hand OA fulfilling ACR criteria were treated with prednisolone, has been analysed. Patients had signs of synovial inflammation, a VAS finger pain of ≥30 and showed flaring ≥20 upon NSAID washout. The primary endpoint of this trial was VAS finger pain (0-100) at week 6.

Neuropathic pain was measured at baseline and after treatment by the painDETECT questionnaire, consisting of questions on pain quality, pain intensity over time and radiating pain. Total score: -1 to 38. Scores< 12 unlikely, scores 13-18 undetermined, scores >18 likely neuropathic pain. QoL was measured with physical component scale (PCS) of Short-Form 36 (SF36; 0-100), comorbidities with the Self-administered Comorbidities Questionnaire (SCQ; 0-45); radiographic severity with Kellgren-Lawrence (KL) sumscore (0-120). OMERACT-OARSI responder criteria were used to determine response on prednisolone.

Association of patient characteristics with neuropathic pain was analysed with multivariate multinominal logistic regression with painDETECT categories as dependent variable. Association of neuropathic pain with QoL was analysed with multivariate linear regression, adjusted for age, sex, BMI, VAS finger pain, SCQ score and KL sumscore, with PCS as dependent variable. Response of neuropathic pain to prednisolone was analysed with generalised estimating equations. Association of neuropathic pain at baseline with response to treatment were analysed using chi-squared tests.

Results: 91 Patients had complete painDETECT data at baseline (mean 12.8 (SD 5.9)). Of these, 53% had no neuropathic pain, 31% were undetermined and 16% had neuropathic pain. Higher painDETECT scores at baseline were associated with lower age, female sex, less radiographic damage and more comorbidities in multivariate analysis (table 1).

Patients with likely neuropathic pain had a lower QoL ( PCS -6.5 (95%CI -10.4 to -2.6), than those without (painDETECT < 13). Neuropathic pain did not change during the trial in both treatment groups, and there was no difference in painDETECT scores between the groups (between group difference mean -1.7 (95%CI -3.9 to 0.4)). VAS pain improved more in the prednisolone group than in the placebo group (between group difference mean -16.5 (95%CI -26.1 to -6.9)) (figure 1). In this study we could not show an association between the presence of neuropathic pain at baseline and OMERACT-OARSI response to treatment (data not shown).

Conclusion: Patients with inflammatory hand OA and additional neuropathic pain are more often female and have more comorbidities, and report a lower QoL, than those without. Neuropathic pain seems unresponsive to anti-inflammatory therapy. Clinicians should be aware of the presence of neuropathic pain in their patients as these findings might implicate that this kind of pain should be specifically targeted.


Disclosure: C. van der Meulen, None; L. van de Stadt, None; F. Kroon, None; M. Kortekaas, None; A. Boonen, AbbVie, 2, Galapagos, 5, Lilly, 5, Celgene, 2, UC, 5; S. Böhringer, None; M. Reijnierse, None; F. Rosendaal, None; N. Riyazi, None; M. Starmans, None; F. Turkstra, None; J. Van Zeben, None; C. Allaart, None; M. Kloppenburg, Dutch Arthritis society, 2.

To cite this abstract in AMA style:

van der Meulen C, van de Stadt L, Kroon F, Kortekaas M, Boonen A, Böhringer S, Reijnierse M, Rosendaal F, Riyazi N, Starmans M, Turkstra F, Van Zeben J, Allaart C, Kloppenburg M. Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/neuropathic-pain-in-inflammatory-hand-osteoarthritisoa-lowers-quality-of-life-and-may-require-another-approach-than-anti-inflammatory-treatment/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neuropathic-pain-in-inflammatory-hand-osteoarthritisoa-lowers-quality-of-life-and-may-require-another-approach-than-anti-inflammatory-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.